Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
相关临床试验
47
25 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2005
进行中（未招募）
25
53.2%
已完成
19
40.4%
招募中
3
6.4%
暂无批准数据
暂无资讯文章
